NCT04485702View on ClinicalTrials.gov

Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

August 29, 2020

Study Completion Date

August 29, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

Midazolam injection

2mg IV

DRUG

Ketamine Injectable Product

6mg IV

DRUG

MELT-100

midazolam 3mg and ketamine 25mg SL tablet

Trial Locations (1)

78217

WWCT, San Antonio

Sponsors

Collaborators (1)

Worldwide Clinical Trials
All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

Melt Pharmaceuticals

INDUSTRY